<DOC>
	<DOCNO>NCT00003126</DOCNO>
	<brief_summary>The purpose study assess efficacy post-operative high-dose bolus interleukin-2 ( IL-2 ) patient high-risk renal cell carcinoma ( RCC ) .</brief_summary>
	<brief_title>Interleukin-2 Treating Patients With Stage III Stage IV Kidney Cancer</brief_title>
	<detailed_description>The primary objective prospective , randomize , control trial compare disease-free overall survival patient stage III IV high-risk renal cell carcinoma ( RCC ) treat adjuvant high-dose interleukin-2 v observation alone . Patients stratify accord disease classification randomize one course IL-2 [ 600,000 U/kg every 8 hour day 1 5 day 15 19 ( maximum 28 dos ) ] observation .</detailed_description>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria An Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate organ function define white blood cell ( WBC ) count 4,000/L ; platelet count 100,000/L ; Hemoglobin level 10 g/dL ; serum creatinine 1.5 mg/dL creatinine clearance 60 mL/min ; direct bilirubin level 1.5 mg/dL . Forced expiratory volume 1 second 2.0 L 75 % predict height age preenrollment pulmonary function test . No history evidence cardiac disease ECG No prior systemic treatment RCC , patient may receive prior locoregional radiation therapy solitary resectable metastasis , must undergo surgical resection enrollment . No prior history invasive malignancy past 5 year Human immunodeficiency virus ( HIV ) negative Female patient must pregnant plan become pregnant Exclusion criterion â€¢ Age young 16</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>renal cell cancer</keyword>
	<keyword>renal cell carcinoma</keyword>
	<keyword>interleukin-2</keyword>
</DOC>